EF-5 is a hypoxia marker used to identify hypoxic cells; it serves as a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs; EF-5 binding correlates strongly with bioreductive prodrug activation and DNA damage at the individual tumor level; it enables oxygen-dependent detection of hypoxia in tumors via monoclonal antibody-based binding assays; its binding can be visualized in frozen tissues using fluorescence microscopy with optional hematoxylin and eosin counterstaining for light microscopic analysis; tumor hypoxia distribution can also be assessed at the single-cell level using flow cytometry.